Immune checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1) and programmed death ligand-1 (anti-PD-L1) pathways have been extensively assessed in multiple tumour types including gastric cancers. The gene discussed is CD274; the disease is neoplasm.